Abstract
Acromegaly is a chronic systemic disease with many complications and is associated with increased mortality when not adequately treated. Substantial advances in acromegaly treatment, as well as in the treatment of many of its complications, mainly diabetes mellitus, heart failure, and arterial hypertension, were achieved in the last decades. These developments allowed change in both prevalence and severity of some acromegaly complications and furthermore resulted in a reduction of mortality. Currently, mortality seems to be similar to the general population in adequately treated patients with acromegaly. In this review, we update the knowledge in complications of acromegaly and detail the effects of different acromegaly treatment options on these complications. Incidence of mortality, its correlation with GH (cumulative exposure vs last value), and IGF-I levels and the shift in the main cause of mortality in patients with acromegaly are also addressed.
Original language | English (US) |
---|---|
Pages (from-to) | 268-332 |
Number of pages | 65 |
Journal | Endocrine reviews |
Volume | 40 |
Issue number | 1 |
DOIs | |
State | Published - Oct 10 2018 |
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism
- Endocrinology